The effects of intranasal esketamine (84 mg) and oral mirtazapine (30 mg) on on-road driving performance: a double-blind, placebo-controlled study

Aurora J. A. E. van de Loo 1,2 · Adriana C. Bervoets 1 · Loes Mooren 1 · Noor H. Bouwmeester 1 · Johan Garssen 1,3 · Rob Zuiker 4 · Guido van Amerongen 4 · Joop van Gerven 4 · Ewa Wajs 6 · Joris C. Verster 1,2,7

Received: 18 January 2017 / Accepted: 17 July 2017 / Published online: 28 July 2017 © The Author(s) 2017. This article is an open access publication

Abstract

Rationale The purpose of this study is to evaluate the single dose effect of intranasal esketamine (84 mg) compared to placebo on on-road driving performance. Mirtazapine (oral, 30 mg) was used as a positive control, as this antidepressant drug is known to negatively affect driving performance.

Methods Twenty-six healthy volunteers aged 21 to 60 years were enrolled in this study. In the evening, 8 h after treatment administration, participants conducted the standardized 100-km on-road driving test. Primary outcome measure was the standard deviation of lateral position (SDLP), i.e., the weaving of the car. Mean lateral position, mean speed, and standard deviation of speed were secondary outcome measures. For SDLP, non-inferiority analyses were conducted, using +2.4 cm (relative to placebo) as a predefined non-inferiority margin for clinical relevant impairment.

Results Twenty-four participants completed the study. No significant SDLP difference was found between esketamine and placebo ($p = 0.7638$), whereas the SDLP after mirtazapine was significantly higher when compared to placebo ($p = 0.0001$). The upper limit of the two-sided 95% confidence interval (CI) of the mean difference between esketamine and placebo was +0.86 cm, i.e., <+2.4 cm, thus demonstrating that esketamine was non-inferior to placebo. Non-inferiority could not be concluded for mirtazapine (+3.15 cm SDLP relative to placebo). No significant differences in mean speed, standard deviation of speed, and mean lateral position were observed between the active treatments and placebo.

Conclusions No significant difference in driving performance was observed 8 h after administering intranasal esketamine (84 mg) or placebo. In contrast, oral mirtazapine (30 mg) significantly impaired on road driving performance.

Keywords Driving · SDLP · Esketamine · Mirtazapine · Depression

Introduction

Despite efforts to improve automobile safety and decrease unsafe driving practices, road trauma remains a serious public health problem (World Health Organization 2009). Psychoactive drugs that affect the central nervous system have the potential to impair driving performance (Walsh et al. 2008). Various factors leading to road accidents after taking psychoactive drugs involve poor vehicle control, impairment of basic driving skills, and impaired decision-making, which increase the risk of accidents during driving (Coranza et al. 2012; Mozayani 2002; Schifano et al. 2015).
The anesthetic and sedative use of ketamine is well-documented. Intranasal ketamine is an anesthetic of choice for patients with acute injury in moderate-to-severe pain in emergency conditions (Shrestha et al. 2016; Yeaman et al. 2014). Also, rapid antidepressant effects can be achieved using intranasal ketamine with low-treatment-associated adverse events (Lapidus et al. 2014). Anesthetic as well as sub-anesthetic concentrations of ketamine have shown to produce neuropsychological effects and rapid mood-enhancing actions in electroconvulsive therapy for treatment-resistant depression, while anesthetic concentrations result in greater magnitudes of antidepressive and cognitive protection (Zhong et al. 2016). The psychotomimetic effects of ketamine are dose-dependent and are avoidable when used at maximal anesthetic doses (Järventausta et al. 2015). The effect of ketamine on depression will also be reached at doses lower than the typical anesthetic doses, and at that low dose level, side-effects are generally mild and transient (Bobo et al. 2016).

Ketamine’s psychomimetic effects including modulation of cognitive processes, emotional responses, memory, and learning (Aalto et al. 2005; Duan et al. 2013; Seeman et al. 2005) could be attributed to its activity on cholinergic systems (postanesthetic delirium) (Hustveit et al. 1995), memory learning attention (Kohrs and Durieux 1998), or adrenergic and dopaminergic systems (Vollenweider et al. 2000; White and Ryan 1996). However, the exact mechanism of action of ketamine contributing to these effects is not well-known and thus remains to be elucidated. Ketamine is a racemic mixture consisting of two enantiomers, R(−) and S(+) ketamine (Zeilhofer et al. 1992). Esketamine (s-[+]ketamine enantiomer) is a non-competitive, subtype non-selective, activity-dependent N-methyl-D-aspartate (NMDA) receptor antagonist which has threefold to fourfold higher affinity for NMDA receptors and threefold anesthetic potency compared with the R(−)-ketamine enantiomer (Kohrs and Durieux 1998; Oye et al. 1992; Vollenweider et al. 1997). The antidepressant effect of esketamine is thought to result from preferential blocking of NMDA receptors on rapid firing inhibitory GABAergic interneurons, which in turn enhances the activity of glutamatergic neurons by increasing the presynaptic release of glutamate and stimulation of postsynaptic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (Duman et al. 2012; Sanacora et al. 2008). Together, these actions potentiate the release of BDNF and activation of its downstream neurotrophic intracellular signaling pathways that result in increased synaptic protein synthesis and synaptogenesis, ultimately restoring synaptic function (Duman et al. 2012; Sanacora et al. 2008). Furthermore, the psychomimetic effects of esketamine have been attributed to its potential to release dopamine in the striatum (Hashimoto 2017).

The anesthetic state of patients with detachment from the environment and self under ketamine effect was best described by the term “dissociation” (Järventausta et al. 2015). The non-medical use of low-dose (0.15 mg/lb–0.33 mg/kg) ketamine either as an inhalation or i.v. injection can cause mild dissociative effects, visual and auditory hallucinations, and feeling of distortions of time, space, and reality. Moreover, high doses (2.2 mg/kg) may induce severe dissociation, known as a “K-hole,” in which individuals experience detachment from reality and severe distortions in consciousness (Muetzelfeldt et al. 2008), neurobehavioral performance deficits (sustained and divided attention) (Passie et al. 2005), reduced reaction time, and subjective assessments of alertness (Micallef et al. 2002) for up to 3 days after ketamine use. Of note, subjective feelings of permuted perception could prove lethal as far as driving is concerned (Giorgetti et al. 2015; Muetzelfeldt et al. 2008).

In Hong Kong, available reports have documented 45% ketamine positivity in intoxicated drivers involved in non-fatal traffic accident (Wong et al. 2010) and 9% positivity in fatal crashes (Cheng et al. 2005). Neurocognitive and psychomotor deficits associated with ketamine use reduce an individuals’ ability to effectively and simultaneously interpret and organize incoming visual, auditory, and tactile information and concurrently impede appropriate behavioral reactions, which may result in car crashes due to increased lane deviation, reduced reaction and braking time, and greater steering deviations (Hayley et al. 2015). Due to sparse observational roadside drug studies, controlled examination of sub-anesthetic doses of ketamine or other drugs of abuse on driving performance is required for further validation (Stough et al. 2012). The 2012 US package insert for ketamine states that patients should be cautioned that driving an automobile, operating hazardous machinery, or engaging in hazardous activities should not be undertaken for 24 h or more (depending upon the dosage of ketamine hydrochloride and consideration of other drugs employed) after anesthesia. It is not clear to which extent this 24-h period is supported by data or chosen arbitrarily. Moreover, as esketamine is administered at a sub-anesthetic dose, the period during which the subject would not be able to drive a car or operate a machine could be shorter compared to after its use as an anesthetic.

The objective of this study was to evaluate the effect of intranasal esketamine compared to placebo and a positive control mirtazapine, on driving performance using the mean difference of the standard deviation of lateral position (SDLP) parameter of an on-the-road driving test.

Methods

Study design

This was a single-center, double-blind, double-dummy, randomized, three-way crossover study in healthy men and
women. The study comprised an eligibility screening examination (between 21 days and 1 day prior to the first dose administration), a three-way cross-over double-blind, a single dose treatment phase, and a follow-up examination (within 7 to 10 days after the last dose administration). Between each test day, a washout period of at least 6 days was scheduled. The study was approved by the BEBO Medical Ethics Committee, and subjects were paid for participation in the study. The study was sponsored by Janssen Research and Development, and conducted in collaboration between the Centre for Human Drug Research, Leiden, the Netherlands (clinical assessments), and Utrecht University (driving tests).

Participants

Twenty-six healthy men and women, aged 21 to 60 years, who met all inclusion and none of the exclusion criteria, were enrolled in this study. Subjects had to have a valid driving license for more than 3 years, have driven at least 5000 km in the past year, and were to be driving a car on a regular basis. They were included if they had a body mass index (BMI) between 18 and 30 kg/m² and a body weight no less than 45 kg. Subjects had to have normal visual acuity (corrected or uncorrected). Subjects with mental or physical disease were excluded, and the use of psychoactive medication known to affect driving performance was not allowed. Subjects were tested for drugs of abuse and alcohol use at entry in the clinical research center. Subjects who withdrew from the study were replaced in order to have the requisite 24 participants who completed the study.

Treatments

To ensure blinding, treatments were administered using a double-dummy technique: on each test day, participant received both an intranasal and oral treatment. On each test day, subjects received one of the following treatments: (1) intranasal esketamine (84 mg) and oral placebo, (2) intranasal placebo and oral mirtazapine (30 mg), or (3) intranasal placebo and oral placebo. Intranasal esketamine was supplied in a nasal spray pump. The device delivered 16.14 mg esketamine hydrochloride (14 mg esketamine base) per 100-μL spray. Intranasal placebo was supplied by the sponsor in a nasal spray pump. The placebo device delivered 0.1 μg of denatonium benzoate per 100 μL spray. During screening, participants were trained to use the intranasal device. Oral mirtazapine was supplied as over encapsulated tablets of 30 mg mirtazapine. Oral placebo was supplied as color- and size-matched capsules.

Study procedures

In the morning, subjects reported at the Center for Human Drug Research in Leiden. Before administration of the treatment, participants were not allowed to eat for 2 h, and not to drink any fluids for 30 min. Standard safety assessments included physical examination, vital signs, 12-lead ECG, clinical chemistry, hematology, urine pregnancy tests (for women of childbearing potential only), and urinalysis. Study medications were self-administered (under medical supervision) in the morning at approximately 11:30 or 13:00 h. Subjects remained in the clinic, and received a light meal approximately 2 h after dosing. The on-road driving test was scheduled in the evening, 8 h after treatment administration. The potential effects of intranasal esketamine on dissociative symptoms, psychosis, and suicidal ideation and behavior were evaluated by the use of rating scales (Clinician Administered Dissociative States Scale [CADSS], 4-item positive symptom subscale of the Brief Psychiatric Rating Scale [BPRS+], and the Columbia Suicide Severity rating Scale [C-SSRS]) that were completed by the investigator. Approximately 1 h before the scheduled start of the driving test, participants were transported from the clinic to Utrecht. Just before transportation, i.e., 6 to 7 h after treatment, a blood sample was taken to determine plasma concentrations of esketamine, its metabolite noresketamine, and mirtazapine. Driving tests were conducted at 7.30 p.m. or 9 p.m., approximately 8 h after treatment administration. After completion of the driving test, subjects were transported back to the clinic in Leiden, where adverse events were reported.

The on-road driving test

During screening, subjects were trained once to obtain baseline performance on the driving test. Subjects had to perform a standardized on-the-road driving test (Verster and Roth 2011). They had to operate a specially instrumented vehicle on a public highway during normal traffic on a 100-km track between the cities of Utrecht and Arnhem (the Netherlands). They were instructed to drive with a steady lateral position (as straight as possible) and a constant speed of 95 km/h on the right (slower) traffic lane. They were allowed to overtake a slower driving vehicle in the same traffic lane. A licensed driving instructor who had access to dual controls sat on the passenger’s seat to guard the safety of the participant during the driving test. A computer in the backseat of the car continuously recorded the speed and position of the car within the traffic lane. The standard deviation of the lateral position (SDLP, cm), i.e., the weaving of the car, is the primary outcome measure (Fig. 1). SDLP was calculated after off-line editing of the data that was disturbed by events (e.g., overtaking a slower car, traffic jams). As illustrated by Fig. 1, when vehicle control is reduced (e.g., when sleepy or after using sedative drugs), SDLP values increase (i.e., more weaving of the car). SDLP has been proven to be a robust measure within participants, capable to demonstrate dose-dependent driving impairment (Verster and Mets 2009; Verster and
Roth 2011). As a cutoff value for clinically impaired driving impairment, usually one refers to the SDLP increase relative to placebo of +2.4 cm (Louwerens et al. 1987), which was observed when driving after the consumption of alcohol to reach a blood alcohol concentration (BAC) of 0.05%, i.e., the legal limit for driving in many countries.

The secondary parameter was the standard deviation of speed (SDS, km/h). Control variables were mean lateral position (MLP, +/- cm) and mean speed (MS, km/h). Driving tests were stopped before completion if the driving instructor or the participant felt it was unsafe to continue.

Subjective assessments

The Groningen Sleep Quality Scale (GSQS) is a participant-reported assessment used to assess the quality of the previous night sleep (Mulder-Hajonides van der Meulen WREH 1980). It consists of 15 items, and scores range from 0 to 14.6. In general, if sleep was unrestricted and undisturbed, participants score 0 to 2 points. A higher score (6 to 7) indicate disturbed sleep. The GSQS was completed before treatment administration. The test day was postponed when GSQS scores were higher than 6.

The Karolinska Sleepiness Scale (KSS) is a subject-reported assessment used to rate sleepiness on a scale of 1 to 9, ranging from “extremely alert” (1) to “very sleepy, great effort to keep awake, fighting sleep” (Åkerstedt and Gillberg 1990). The KSS was completed directly before the driving test.

After the driving test, subjects indicated the perceived quality of their driving performance on a scale ranging from “I drove exceptionally poorly” to “I drove exceptionally well” around a midpoint of “I drove normally” (Verster and Roth 2011). The level of effort they had to invest to complete the driving test was indicated on a 15-cm scale, with multiple markings ranging from “absolutely no effort” to “extreme effort” (Zijlstra and van Doorn 1985).

Sample size

The sample size and power estimation were based upon the SDLP, the primary end point of the study. A non-inferiority margin of 2.4 cm in SDLP (associated with blood alcohol content of 0.05%) that was considered clinically relevant was used for the power calculation. Assuming that the true difference in SDLP between esketamine and placebo was 0.63 cm, with a two-sided significance level of 0.05 (one-sided 0.025) and a SD of a difference in paired case of 2.97 cm (i.e., within-subject SD in a crossover of 2.1 cm), a sample size of 24 subjects achieved 80% power to detect non-inferiority between treatments (one-sided paired t test).

Statistical analysis

The statistical analysis was performed using Statistical Analysis Software (SAS), version 9.2.

Statistical analysis was conducted using an analyses of variance (ANOVA) model with treatment, sequence, period, and gender as fixed effects, and subjects within sequence as a random effect. Pairwise comparisons between the treatments and placebo were conducted. A similar ANOVA model was used for analyses of secondary parameters (SDS, MLP, and MS).

In addition, for SDLP only, a non-inferiority test was conducted. Non-inferiority between each active treatment and placebo was concluded if the upper limit of the two-sided 95% confidence interval of the mean difference between treatment and placebo was <2.4 cm.

Results

A total of 26 subjects participated in the study. Of these, two subjects did not complete the study. One subject was withdrawn due to an adverse effect (atrial fibrillation, unrelated to the study drug) and the other subject discontinued study.
participation due to withdrawal of consent. None of the subjects had a total GSQS score greater than 6 on any test day. Demographics of the 24 subjects that were included in the statistical analyses are summarized in Table 1.

**Driving performance**

Results of the driving test are summarized in Table 2. Mean (SE) SDLPs were 17.10 cm (0.92), 19.38 cm (0.91), and 17.25 cm (0.92) after esketamine, mirtazapine, and placebo, respectively. The upper limit of the two-sided 95% CI of the mean difference between esketamine and placebo was +0.86 cm. As this is below the prespecified non-inferiority margin of +2.4 cm, esketamine was non-inferior to placebo. In contrast, the upper limit of the two-sided 95% CI of the mean difference between mirtazapine and placebo (+3.15 cm) was greater than the non-inferiority margin of +2.4 cm.

No significant differences from placebo were found for standard deviation of speed, as well as the control variables mean speed and mean lateral position. Individual driving performances, i.e., ΔSDLP (treatment – placebo), are summarized in Fig. 2.

**Subjective driving assessment**

Compared to placebo (12.10 cm), perceived driving quality was significantly lower after mirtazapine (8.8 cm, \( p = 0.0029 \)), perceived driving quality scores were also lower after esketamine (10.11 cm), but this difference was not statistically significant (\( p = 0.0676 \)).

Compared to placebo (4.58 cm), perceived effort to perform the driving test was significantly higher (more effort) after both esketamine (6.47 cm, \( p = 0.0169 \)) and mirtazapine (6.29 cm, \( p = 0.0278 \)).

**Stopped driving tests**

Two subjects did not complete the driving tests after administration of esketamine, due to adverse events. One of these subjects (no. 21 in Fig. 2) also declined the driving test with mirtazapine due to ongoing nausea and dizziness. This subject reported paresthesia and headache during the driving test after esketamine. Although the driving of the subject was assessed as safe by the driving instructor, the subject stopped the driving test after 46 km. The second subject who discontinued the driving test (no. 8 in Fig. 2) experienced blinding by the traffic lights which could be associated with esketamine or underlying migraine. For this subject, driving was assessed as impaired by the driving instructor, with a potential safety impact, and the test was stopped after 35 km. This subject had also reported the adverse event of migraine in the prior study period (after administration of placebo). Importantly, both subjects timely verbalized their wish to stop the test and reported their adverse events, thus minimizing any risk of accident. As is evident from Fig. 2, both subjects’ actual driving

### Table 1

|                      | Men (N = 12) | Women (N = 12) | Overall (N = 24) |
|----------------------|-------------|---------------|-----------------|
| Age (years)          | 26.3 (8.25) | 28.0 (9.01)   | 27.1 (8.49)     |
| Weight (kg)          | 80.3 (9.75) | 66.2 (9.70)*  | 73.3 (11.95)    |
| Height (cm)          | 183.8 (7.73)| 170.5 (6.41)* | 177.2 (9.72)    |
| BMI (kg/m²)          | 23.7 (2.15) | 22.7 (2.04)   | 23.2 (2.12)     |

Mean (SD) are shown

**BMI** body mass index, **SD** standard deviation

Significant differences (\( p < 0.05 \) based on a two-sample \( t \) test) between men and women

### Table 2

|                      | Esketamine (84 mg) Mean (SE) | Mirtazapine (30 mg) Mean (SE) | Placebo Mean (SE) |
|----------------------|-----------------------------|-------------------------------|-------------------|
| SDLP (cm)            | 17.10 (0.92)                | 19.38 (0.91)*                | 17.25 (0.92)      |
| SDS (km/h)           | 2.40 (0.16)                 | 2.49 (0.16)                  | 2.28 (0.16)       |
| MLP (cm)             | 10.85 (2.57)                | 8.33 (2.53)                  | 8.73 (2.55)       |
| MS (km/h)            | 97.96 (0.35)                | 97.72 (0.34)                 | 97.79 (0.34)      |

**SDLP** standard deviation of lateral position, **SDS** standard deviation of speed, **MLP** mean lateral position, **MS** mean speed, **SE** standard error

*Significant differences from placebo (\( p < 0.05 \))

Fig. 2 Individual driving performance. Difference scores (ΔSDLP, treatment – placebo) are depicted. The dotted lines represent the cutoff values for non-inferiority (+2.4 cm) and superiority (−2.4 cm). Same numbers are same subjects. Subjects no. 8 and 21 had driving tests that were stopped before completion (depicted in black). Note that subject no. 21 did not perform the driving test in the mirtazapine condition. Abbreviations: **SDLP** standard deviation of lateral position, **PLAC** placebo.
performance before stopping the test, as expressed in ΔSDLP, was below the upper limit of the prespecified non-inferiority margin of +2.4 cm.

**Blood plasma concentrations**

All subjects exhibited measurable concentrations of esketamine, noresketamine, and mirtazapine prior to the driving test. Plasma concentrations of esketamine, noresketamine, and mirtazapine were 15.4 ng/mL (4.81), 80.9 ng/mL (32.7), and 28.0 ng/mL (8.45), respectively. Non-parametric Spearman’s r correlations between ΔSDLP (treatment – placebo) and plasma drug concentration were not significant for esketamine (r = −0.243, p = 0.253), noresketamine (r = −0.294, p = 0.163), and mirtazapine (r = 0.258, p = 0.235).

**Adverse effects**

The incidence of treatment-emergent adverse events was higher after esketamine (100.0%) compared to mirtazapine (88.5%) and placebo (37.5%). After esketamine, the most frequently reported adverse events were dizziness (66.7%), dissociation (50.0%), nausea (45.8%), paraesthesia (45.8%), headache (45.8%), dysgeusia (29.2%), feeling drunk (29.2%), and fatigue, vomiting and somnolence, euphoric mood, and blurred vision (each reported by 20.8% of participants). Most of the adverse events observed after esketamine were mild in severity, transient, and resolved within 2–3 h after dosing. After mirtazapine, the most frequently (≥20%) reported adverse events were somnolence (65.4%) and fatigue (26.9%), typically lasting several hours to several days. After placebo, the most commonly reported adverse event was headache (12.5%).

**Discussion**

On-road driving performance, as measured by SDLP, was not significantly impaired 8 h after intranasal administration of esketamine (84 mg). The upper limit of the two-sided 95% CI of the mean difference between esketamine and placebo was +0.86 cm, which is above the non-inferiority margin of +2.4 cm. Hence, it can be concluded that esketamine was not inferior to driving after placebo. In contrast, driving was significantly impaired 8 h after oral administration of mirtazapine (30 mg). The mean difference between mirtazapine and placebo was +3.15 cm, well above the upper limit of the two-sided 95% CI. As mirtazapine served as positive control, the latter was anticipated and the results confirm assay sensitivity.

While this is the first study investigating driving performance after esketamine, several studies have examined mirtazapine’s effect on on-road driving. Verster et al. (2015) reviewed three on-road and four driving simulator studies, which revealed dose-dependent driving impairment the morning following bedtime administration of mirtazapine (15 or 30 mg). The observed magnitude of driving impairment relative to placebo was comparable to that seen when driving with a BAC of 0.05%. Hence, mirtazapine is a suitable comparator (positive control) in driving tests examining antidepressant drugs. Of note, whereas in the previous studies mirtazapine was administered at bedtime and after a full night of sleep, driving tests were performed in the morning, in the current study the drug was administered in the morning and driving tests were in the early evening, with no opportunity to sleep during the day.

Two driving tests after treatment with esketamine were stopped before completion, and another driving test was not started after treatment with mirtazapine. It is sometimes suggested that when driving tests are stopped before completion this is evidence that a drug is unsafe. However, the number of stopped tests is actually a poor predictor of a drug’s effects on driving performance. In fact, a review of 50 driving studies revealed that in 14 of these clinical trials driving tests are also stopped after treatment with placebo (Verster and Roth 2012).

It is important to examine in detail the causes of premature stopping the respective driving tests. Stopping a driving test is a subjective decision that depends on the awareness of performance impairment and risk perception by either the driver or the driving instructor (Verster and Roth 2012). Sometimes, a clear association with drug effects is evident, for example, if drivers are very sleepy due to administering drugs with sedative properties. However, drivers themselves can have many other reasons for stopping the driving tests. These may not be related to treatment-emergent adverse effects or to actual performance impairment. In other words, tests can be stopped if no significant increase in SDLP is observed and no takeover maneuvers were needed by the driving instructor (Verster and Roth 2012). Therefore, it may be concluded that stopped driving tests are a poor indicator to what extent it is safe to drive with a certain drug. Also in the current study, actual driving performance in the two stopped driving tests was within the non-inferiority boundaries (Fig. 2). One of the subjects who stopped her driving test after esketamine seems more sensitive to drug effects than most other participants, as she also refused to start her driving test after mirtazapine. Taken together, although two driving tests were stopped before completion, this should not be viewed as supportive evidence that driving after esketamine is unsafe.

Blood plasma concentrations of esketamine, noresketamine, and mirtazapine did not correlate significantly with performance on the driving test (i.e., treatment – placebo differences). Driving is an example of complex behavior, and at baseline large differences can be seen between individual drivers, as expressed in SDLP values ranging from around 10 to 30 cm (Verster and Roth 2011). However, the absolute difference in
SDLP (treatment – placebo) is fairly constant among drivers with different baseline SDLPs (Verster and Roth 2011), despite sometimes large differences in blood drug concentrations. A similar poor relationship between blood drug concentration and individual ΔSDLPs has been reported for benzodiazepine drugs (Verster and Roth 2013). As expected, esketamine treatment was associated with adverse events related to nervous system and psychiatric disorders in nearly all patients. However, these adverse events were transient and resolved in most patients within 2–3 h after dosing including dissociative symptoms which was observed in 13 (50%) patients.

Previous reports suggest that the most common adverse events associated with esketamine treatment are drowsiness, dizziness, drunkenness, sensation of floating body experience, and distorted vision/hearing (Persson et al. 2002; Segmiller et al. 2013; Vollenweider et al. 1997). Consistent with this, the most frequently reported adverse events in the present study were dizziness, dissociation, nausea, paraesthesia, headache, dysgeusia, feeling drunk, fatigue, vomiting and somnolence, euphoric mood, and blurred vision. There were no new or unexpected safety concerns noted with the administration of intranasal esketamine during the study.

The current study has several potential limitations that should be addressed. First, in this study driving tests were performed in the evening, after being awake during the day, 8 h after treatment administration. This may have had a negative impact on the participants’ alertness levels and sleepiness. Also contributing to increased sleepiness was the fact that tests were conducted after sundown. However, as this was a cross-over trial, possible effects of evening driving would have been experienced equally on each test day and patients taking these medications could have to drive in the evening or after dark in real-world conditions. Second, as only a single dose of each treatment was administered, it is unknown if driving performance improves after repeated treatment administration. For many drugs, tolerance is seen after repeated drug use in terms that users experience less side effects and driving performance slowly returns to baseline (placebo) performance levels. This is for example seen after repeated administration of mirtazapine (Verster et al. 2015). Future studies should therefore examine the effects on driving ability of sub-chronic use of esketamine. In the current study, the time between treatment administration and driving was 8 h. If indeed after sub-chronic use tolerance develops to the effects of esketamine, the time between treatment administration and driving may be reduced, without compromising safety. However, this needs to be confirmed in future studies.

A limitation may be regarded that the current study was conducted in healthy volunteers as opposed to patients with major depression. This was however not a limitation but done on purpose. If one is interested in the pharmacological effects of a drug on driving, healthy volunteers should be tested. That way, assessments are not affected by health- or disease-related factors. For example, in case assessments were made in depressed patients instead of healthy participants, drug-disease interactions could obscure the study outcome in that adverse drug effects may be reversed by possible treatment effects (i.e., a reduction in depression scores). It is then difficult to interpret the study outcome. If a drug has been investigated in healthy volunteers, a next step may be to further examine its effects on driving in the intended patient population. Also for esketamine, it would be interesting to examine its effects in depressed patients, both after single-dose administration and after sub-chronic use. Finally, as esketamine was administered in the morning and driving tests were performed in the evening, it may be interesting if the absence of effects on driving performance is also seen when esketamine is administered in the evening and the driving tests are performed next morning. Future research should address these topics.

In summary, administration of intranasal esketamine did not significantly impair driving performance 8 h thereafter. Future research should confirm these findings in patients with major depression, and investigate the effects of chronic esketamine use.

Acknowledgments The authors acknowledge Ashwini Patil, MS, ISMPP CMPP, for medical writing assistance and Dr. Himabindu Gutha, PhD (both from SIRO Clinpharm Pvt. Ltd.), for answering journal queries, as well as Harry Ma, PhD (Janssen Research & Development, LLC), for additional editorial support for this manuscript.

Compliance with ethical standards

Declaration of interest This study was supported by Janssen Research and Development, and conducted by Utrecht University and the Centre for Human Drug Research.

Joris Verster has received grants/research support from the Dutch Ministry of Infrastructure and the Environment, Janssen Research and Development, Nutricia, Red Bull, Sequential, and Takeda and has acted as a consultant for the Canadian Beverage Association, Centraal Bureau Drogisterijbedrijven, Coleman Frost, Danone, Deenox, Eisai, Janssen, Jazz, Purdue, Red Bull, Sanoﬁ-Aventis, Sen-Jam Pharmaceutical, Sepracor, Takeda, Transcept, Trimbos Institute, and Vital Beverages. Johan Garsen is a part-time employee of Nutricia Research and received research grants from Nutricia research foundation, Top Institute Pharma, Top Institute Food and Nutrition, GSK, STW, NWO, Friesland Campina, CCC, Raak-Pro, and EU. Jaskaran Singh, Peter Van der Ark, Maggie Fedgchin, Randall Morrison, and Ewa Wajs are employees of Janssen Research & Development, LLC, and own stock/stock options in the company. Other authors have no potential conflicts of interest to disclose.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

Aalto S, Halilainen J, Hirvonen J, Kajander J, Scheinin H, Tanila H, Nagren K, Vilkman H, Gustafsson LL, Syvalahti E, Hietala J (2005) Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology 182: 375–382

Åkerstedt T, Gillberg M (1990) Subjective and objective sleepiness in the active individual. Int J Neurosci 52:29–37

Bobo WV, Voort JLV, Crouarkin PE, Leung JG, Tye SJ, Frye MA (2016) Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depression and anxiety

Cheng JY, Chan DT, Mok VK (2005) An epidemiological study on alcohol/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000. Forensic Sci Int 153: 196–201

Corazza O, Schifano F, Simonato P, Fergus S, Assi S, Stair J, Corkery J, Duan TT, Tan JW, Yuan Q, Cao J, Zhou QX, Xu L (2013) Acute ketamine – a single administration of esketamine, but not R-ketamine: a PET study of a model psychosis in humans. Eur Neuropsychopharmacol 23:145–149

Duan TT, Tan JW, Yuan Q, Cao J, Zhou QX, Xu L (2013) Acute ketamine induces hippocampal synaptic depression and spatial memory impairment through dopamine D1/D5 receptors. Psychopharmacology 228:451–461

Duman RS, Li N, Liu RJ, Duric V, Aghajanian G (2012) Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 62:35–41

Giorgetti R, Marcotulli D, Tagliabracci A, Schifano F (2015) Effects of ketamine on psychomotor, sensory and cognitive functions relevant for driving ability. Forensic Sci Int 252:127–142

Hayley AC, Stough C, Verster JC, van de Loo AJ, Downey LA (2015) The green light on ketamine: considerations for on-road safety. Curr Drug Abuse Rev 8:1–2

Hashimoto K, Kakuchi T, Obha H, Nishiyanma S, Tsukada H (2017) Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci 267(2):173–176

Hustveit O, Maureset O, Oye I (1995) Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 77:355–359

Järventaus K, Kampman O, Yli-Hankala A, Leinonen E (2015) S-ketamine for the treatment of depression. Psychiatr Finn 46:11–20

Kohrs R, Durieux ME (1998) Ketamine: teaching an old drug new tricks. Anesth Analg 87:1193–1201

Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimanl L, Feder A, Iosifescu DV, Charney DS, Murrough JW (2014) A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 76:970–976

Loustalot J, Giroirch A, De Vries G, Broekhuysen K, O’Hanlon J (1987) The relationship between drivers’ blood alcohol concentration (BAC) and actual driving performance during high speed travel. In: Noordzij PC and Roszbach R (Eds) Alcohol, drugs and traffic safety. Experpta Medica, Amsterdam, pp 183–192

Micallef J, Guillermain Y, Tardieu S, Hasbroucq T, Possamai C, Jouve E, Blin O (2002) Effects of subanesthetic doses of ketamine on sensorimotor information processing in healthy subjects. Clin Neuropharmacol 25:101–106

Mozayani A (2002) Ketamine-effects on human performance and behavior. Forensic Sci Rev 14:123–131

Muetzelfeldt L, Kamboj S, Rees H, Taylor J, Morgan C, Curran H (2008) Journey through the K-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend 95:219–229

Mulder-Hajonides van der Meulen WREH WJ, Hollander JJ, De Dian IPF, van den Hoofdakker RH (1980) Measurement of subjective sleep quality. European Sleep Research Society pp 98

Oye I, Paulsen O, Maureset A (1992) Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 260:1209–1213

Passie T, Karst M, Wiese B, Emrich HM, Schneider U (2005) Effects of different subanesthetic doses of (S)-ketamine on neuropsychology, psychopathology, and state of consciousness in man. Neuropsychobiology 51:226–233

Persson J, Hasselström J, Maureset A et al (2002) Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur J Clin Pharmacol 57:869–875

Sanacora G, Zarate CA, Krystal JH, Manji HK (2008) Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7:426–437

Schifano F, Orsolini L, Ducio Papanti G, Corkery JM (2015) Novel psychoactive substances of interest for psychiatry. World Psychiatry : Off J World Psychiatr Assoc 14:15–26

Seeman P, Ko F, Tallierco T (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry 10:877–883

Segmüller F, Rüther T, Linhardt A, Padberg F, Berger M, Pogarell O, Müller HJ, Kohler C, Schüle C (2013) Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol 53:996–998

Shrestha R, Pant S, Shrestha A, Batajou KH, Thapa R, Vaidya S (2016) Intranasal ketamine for the treatment of patients with acute pain in the emergency department. World J Emerg Med 7:19

Stough C, King R, Papafotiou K, Swann P, Ogden E, Wesnes K, Downey LA (2012) The acute effects of 3,4-methylenedioxymethamphetamine and d-methamphetamine on human cognitive functioning. Psychopharmacology 220:799–807

Verster JC, Mets MA (2009) Psychoactive medication and traffic safety. Int J Environ Res Public Health 6:1041–1054

Verster JC, Roth T (2011) Standard operation procedures for conducting the on-the-road driving test, and measurement of the standard deviation of lateral position (SDLP). Int J Gen Med 4:359

Verster JC, Roth T (2012) The prevalence and nature of stopped on-the-road driving tests and the relationship with objective performance impairment. Accid Anal Prev 45:498–506

Verster JC, Roth T (2013) Blood drug concentrations of benzodiazepines correlate poorly with actual driving impairment. Sleep Med Rev 17: 153–159

Verster JC, van de Loo AJ, Roth T (2015) Mirtazapine as positive control drug in studies examining the effects of antidepressants on driving ability. J Eur Pharmacol 753:252–256

Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J (1997) Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsychopharmacol : J Eur Coll Neuropsychopharmacol 7:25–38

Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL (2000) Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. J Psychiatr Res 34: 35–43

Walsh JM, Verstraete AG, Huestis MA, Morland J (2008) Guidelines for research on drugged driving. Addiction 103:1258–1268

White JM, Ryan CF (1996) Pharmacological properties of ketamine. Drug Alcohol Rev 15:145–155

Wong OF, Tsui KL, Lam TS, Sze NN, Wong SC, Lau FL, Liu SH (2010) Prevalence of drugged drivers among non-fatal driver casualties

© Springer
presenting to a trauma centre in Hong Kong. Hong Kong Med J = Xianggang Yi Xue Za Zhi / Hong Kong Acad Med 16:246–251

World Health Organization (2009) Global status report on road safety: time for action. World Health Organization, Geneva. Available at: www.who.int/violence_injury_prevention/road_safety_status/2009

Yeaman F, Meek R, Egerton-Warburton D, Rosengarten P, Graudins A (2014) Sub-dissociative-dose intranasal ketamine for moderate to severe pain in adult emergency department patients. Emerg Med Australas 26:237–242

Zeilhofer HU, Swandulla D, Geisslinger G, Brune K (1992) Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol 213(1):155–158

Zhong X, He H, Zhang C, Wang Z, Jiang M, Li Q, Zhang M, Huang X (2016) Mood and neuropsychological effects of different doses of ketamine in electroconvulsive therapy for treatment-resistant depression. J Affect Disord 201:124–130

Zijlstra FRH, van Doorn L (1985) The construction of a scale to measure perceived effort. Report Delft University of Technology, Delft